TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06703177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1826
Description: SHR-1826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-4642
Description: SHR-4642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839
Description: SHR-9839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Injection
Description: Fluorouracil Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate Injection
Description: Calcium Folinate Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Injection
Description: Adebrelimab Injection
Study: NCT06703840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIB-01
Description: LIB-01 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIB-01
Description: LIB-01 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIB-01
Description: LIB-01 oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIB-01 Placebo
Description: LIB-01 Placebo oral suspension
Study: NCT05333445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational program
Description: Education for the management of AF is carried out in a structured way, following the Bowyer model using the following pre-specified subtitles: How the heart works; Causes and risk factors of AF; Symptoms of AF; Goals of treatment in atrial fibrillation ; ''preparation for the ablation procedure''; and Lifestyle Modification. The technique consists of discussing the main subtitles and adapting the visit line to the needs of each patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: risk factors management
Description: identify risk factors and offer guidance based on management strategies for the specific risk factor in each case

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone and e-mail contact
Description: patients will also be provided with a phone number and email to contact the nurse for any concerns outside the designated times within the twelve-month follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: standard care
Study: NCT06397794

Intervention type: OTHER
Intervention: Quantitative surveys and qualitative interview
Description: All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
Study: NCT05968612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet
Description: Film-coated tablet administered orally.
Study: NCT06703996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in check-in/goal-setting discussions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear the InBody Band 3 fitness tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05968612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor 200 mg Film-Coated Tablet Formulation
Description: Film-coated tablet administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor 200 mg Film-Coated Tablet Formulation
Description: Film-coated tablet administered orally.
Study: NCT05912946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. Interferon solution was configured according to the ratio of 3 million IU interferon +49ml normal saline. The urinary tube was clamped and the interferon solution was injected through the water inlet tube and retained for 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sterile sodium hyaluronate solution was injected through the water inlet tube and retained for 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection
Description: The patient was seated in the seat and rested quietly. A three-way urinary tube was indwelled to drain urine. The urinary tube was clamped and the sodium chloride injection was injected through the water inlet tube and retained for 30 minutes.
Study: NCT05014009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA11+ and multidirectional training (MD)
Description: This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by COD technique modification training, which contains exercises aimed at improving COD technique (safer and more effective body re-direction, use of penultimate step, avoiding knee valgus) and COD braking and re-acceleration impulse.~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their COD technique. Participants are encouraged to complete a third training session in their own time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FIFA11+ and linear sprint training (MD)
Description: This intervention initially contains a shortened version of the FIFA11+ injury prevention program including running (straight, hip out, hip in, jump-run-ups), strengthening (planks, squats, nordic hamstring curls), and single-leg balance exercises. The initial part is followed by a linear sprint training, which contains exercises aimed at improving sprint technique (e.g. sagittal arm and leg movement, trunk lean), use of the stretch-shortening cycle, leg stiffness and propulsive impulse .~The duration of each training session is 25-30 minutes. The training is carried out twice per week under supervision with supervisors providing feedback to participants regarding their sprinting technique. Participants are encouraged to complete a third training session in their own time.
Study: NCT06240026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: transauricular vagal nerve stimulation electrodes (NEMOS, CerboMed GmbH, Erlangen, Germany), attached to a digitimer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Earlobe Stimulation
Description: Standard electrodes (Ambu, Neuroline, Bordeaux, France) cut into 0.5cm and 1cm rounds, attached to a digitimer.
Study: NCT05831293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: In each session, three sections were discussed and reviewed: (1) last week's experiences, (2) training, and (3) practice. Each session usually began with mindfulness and meditation exercises, followed by group discussion, review of homework activities, and introduction to new exercises. Participants were asked to complete 15-30 minutes of daily practice each week.
Study: NCT06704048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Standard hospital-based cardiac rehabilitation according to SEPHIA and SWEDEHEART protocols 2 times a week for 12 weeks with individualized physical evaluation before and after the intervention.
Study: NCT06702436

Intervention type: OTHER
Intervention: Observational Study
Description: This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians

Intervention type: OTHER
Intervention: Observational Study
Description: This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians
Study: NCT06702605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004 tablets
Description: XNW5004 will be administered orally as tablets.
Study: NCT06702462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-152A propellant
Description: HFA-152A propellant is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-152A propellant
Description: HFA-152A propellant is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-134A propellant
Description: HFA-134A propellant is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-134A propellant
Description: HFA-134A propellant is administered via oral inhalation
Study: NCT06703372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diode Laser 980 nm, 0.2W
Description: diode laser will be used at an operating wavelength of 980 nm, with adoption of the due safety measures in all cases. Laser irradiation will be applied bilaterally to the skin over the area of the submandibular and parotid glands. Irradiation will be applied externally to the parotid gland on a continuous basis and likewise to the submandibular gland moving the laser very slowly over the gland zone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Diode laser
Description: the tip of the instrument will be sealed with blue rubber to prevent the passage of light
Study: NCT06704035

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early OGTT Results Revealed
Description: Early pregnancy screening with a three-time point (fasting, 1h, 2h) 75g oral glucose tolerance test before 16 weeks' gestation with plasma glucose results revealed to the patient and clinician for appropriate management of any diabetes (gestational and type 2, if diagnosed) from early pregnancy onwards.
Study: NCT06702956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser corticotomy
Description: stimulation of tooth movement during orthodontics treatment using Waterlase MDTM Turbo all-tissue laser therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tooth movement
Description: tooth movement us done using wires and brackets
Study: NCT05838508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Research participants will be assigned to two exercise conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Research participants will be assigned to two exercise conditions.
Study: NCT05182008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Online interactive decision aid on method of early abortion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will be directed to the abortion clinic website
Study: NCT06516549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping rope and informational pamphlet
Description: The provision of a skipping rope and an informational pamphlet to the intervention arm participants will happen during the participant interview within the overall DASH cohort study. The enumerator conducting the survey interview will provide each participant in the intervention group with a skipping rope and pamphlet and will read a short script explaining how to use the rope, outlining the main benefits of physical activity for adolescents, and asking participants to read the pamphlet in their own time.
Study: NCT06236334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELFI lifestyle intervention
Description: A (digital) lifestyle support intervention. Based on anthropometrics, food intake and lifestyle preferences, subjects will receive behavioral lifestyle support, especially with the focus on healthy food intake.
Study: NCT04862052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular management of prior implanted coronary drug eluting stent restenosis
Description: Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravascular management of prior implanted coronary drug eluting stent restenosis
Description: Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular management of prior implanted coronary drug eluting stent restenosis
Description: Intravascular devices will be assessed for the management of prior implanted drug eluting stent restenosis management.
Study: NCT05262023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL593
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL593
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)
Study: NCT06362616

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation
Description: Patients will be treated with 5 x 5.2 Gray (Gy) preoperative accelerated partial breast irradiation of the in situ tumor in the breast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery
Description: Patients will be treated with breast conserving surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node procedure
Description: Patients will undergo a (repeat) sentinel node procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy track removal
Description: The biopsy track will be surgically removed.
Study: NCT04322383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
Study: NCT06515080

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Red Infrascopy
Description: Monitor of regional cerebral oxygen saturation
Study: NCT05037292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAUSE Intervention
Description: Standardized frailty screening and utilization of a frailty review board (PAUSE Board)
Study: NCT06497101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temperament Based Therapy with Support (TBT-S)
Description: Participants included in the intervention arm will receive TBT-S (5-day treatment) in addition to treatment as usual (TAU)
Study: NCT05617898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Didactic Training
Description: The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
Study: NCT04840901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Administered SC.
Study: NCT05346510

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALND Group
Description: ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALND Group
Description: ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALND Group
Description: ALND is performed in patients with positive axillary lymph nodes on CT scan and on AAUS. pALND is performed in patients with negative axillary lymph nodes on CT scan but positive on AAUS.SLNB will be performed for those with negative axillary lymph nodes on CT scan and on AAUS.
Study: NCT06342544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immediate treatment with corticosteroids
Description: Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: addition of rituximab if recurrence
Description: rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
Study: NCT06131918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol, Alpha lipoic acid, Super oxide dismutase
Description: Tab Resveratrol 1500 mg BD Tab Alpha lipoic Acid 600 mg BD Tab Superoxide dismutase 250 mg BD
Study: NCT04982575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Description: Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4 mg
Description: Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study: NCT05820542

Intervention type: OTHER
Intervention: McGrath MAC videolaryngoscope
Description: The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
Study: NCT06131918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Tab Resveratrol 1500 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Tab Alpha lipoic acid 600 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Super Oxide Dismutase
Description: Tab Super oxide dismutase 250 mg BD Tab Placebo 600mg BD Cap Placebo 250mg BD
Study: NCT05222178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMI-103
Description: HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMI-103
Description: HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
Study: NCT06535867

Intervention type: DIAGNOSTIC_TEST
Intervention: mHealth
Description: The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
Study: NCT04317300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brief behavioral therapy
Description: brief behavioral therapy
Study: NCT05025293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: 100ml Zoledronic acid (5mg/100ml) administered intravenously
Study: NCT05445778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine plus Bevacizumab
Description: Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Participants will receive Bevacizumab 15mg/kg every 3 weeks
Study: NCT05025293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: 100ml Zoledronic acid (5mg/100ml) administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 100ml NaCl 9mg/ml administered intravenously
Study: NCT04944342

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study: NCT05225428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Standard genetic counseling
Study: NCT05880485

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: online adaptive radiotherapy
Description: PTV with 5-10 margins covers CTV
Study: NCT05365594

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ankle Movement Boot
Description: Walking boot used for orthopaedic foot injuries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ankle Movement Boot
Description: Walking boot used for orthopaedic foot injuries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVENUp Lift
Description: Orthotic shoe lift worn on contralateral foot to increase leg length

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVENUp Lift
Description: Orthotic shoe lift worn on contralateral foot to increase leg length